Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

144 Results

Guidelines and Advice

Systemic Treatment Emergency Preparedness Guidance Document

Status: Current

Dec 1969

Guidelines and Advice

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Status: Current
ID: GL END 4-19

Updated

Nov 2025

Guidelines and Advice

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

Status: Current
ID: GL 1-22-A
Version: 2

Jul 2022

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Dec 1969

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer

Status: Current
ID: 5-11
Version: 2

Jan 2022

Guidelines and Advice

Systemic Treatments for Unresectable and Metastatic Cutaneous Melanoma

Status: Current
ID: GL 8-12

Updated

Jan 2026

Guidelines and Advice

Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours

Status: Current
ID: 7-11
Version: 3

Mar 2022

Guidelines and Advice

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Status: In-Review
ID: GL 5-3ORG
Version: 2

Dec 1969

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Status: Current
ID: 7-A-2018-2
Version: N/A

Jan 2020

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Dec 1969

Guidelines and Advice

Organizational Guideline for Gynecologic Oncology Services in Ontario

Status: Current
ID: GL 4-11
Version: 2

Updated

Mar 2026

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Systemic Treatment Emergency Preparedness Guidance Document

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer

Systemic Treatments for Unresectable and Metastatic Cutaneous Melanoma

Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Organizational Guideline for Gynecologic Oncology Services in Ontario

Pages